BI 685509

Drug Profile

BI 685509

Alternative Names: BI685509

Latest Information Update: 06 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Boehringer Ingelheim
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Diabetic nephropathies

Most Recent Events

  • 04 Sep 2017 Phase-I clinical trials in Diabetic nephropathies (In volunteers) in South Korea, Japan (PO) (NCT03259464)
  • 29 Aug 2017 Boehringer Ingelheim plans a phase I trial in Healthy volunteers in Japan and South Korea (PO) (NCT03259464)
  • 31 May 2017 Boehringer Ingelheim completes a phase I trial in Healthy volunteers in Germany (NCT03116893)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top